1. From the Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine (Drs. Coulter and Clark) and the Department of Pharmacology and Toxicology (Dr. Clark), University of Otago, Dunedin, New Zealand; and the Netherlands Pharmacovigilance Centre Lareb, ‘s‐Hertogenbosch (Drs. Passier and van Puijenbroek).